Cargando…

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?

Pseudomonas aeruginosa (PA), a gram-negative rod-shaped bacterium, is one of the most common pathogens causing colonization and infection of the respiratory tract and lungs in patients with cystic fibrosis (CF). Antibiotic therapy is the mainstay treatment for PA infection, and tobramycin is one of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karki, Kumar, Sigdel, Santosh, Kafle, Sunam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451513/ https://www.ncbi.nlm.nih.gov/pubmed/34567873 http://dx.doi.org/10.7759/cureus.17326

Ejemplares similares

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
por: Panguluri, Srilekha, et al.
Publicado: (2017)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence
por: Hamed, Kamal, et al.
Publicado: (2017)

Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
por: Olivares, Elodie, et al.
Publicado: (2017)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
por: Hamed, Kamal, et al.
Publicado: (2017)

Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2023)

The emergence of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients on inhaled antibiotics
por: AbdulWahab, Atqah, et al.
Publicado: (2017)

Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
por: Garazzino, Silvia, et al.
Publicado: (2020)

Once daily aerosolised tobramycin in adult patients with cystic fibrosis in the management of Pseudomonas aeruginosa chronic infection
por: Mantero, Marco, et al.
Publicado: (2017)

Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa
por: Murphy, Ronan A., et al.
Publicado: (2022)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis
por: Deschamp, Ashley R, et al.
Publicado: (2017)

Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation
por: Gauthier, Timothy P., et al.
Publicado: (2015)

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis
por: Vázquez-Espinosa, Emma, et al.
Publicado: (2015)

Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation
por: Price, Katherine E., et al.
Publicado: (2015)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review
por: VanDevanter, Donald R, et al.
Publicado: (2011)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report
por: Santos, Roberto P, et al.
Publicado: (2007)

Unknown Renal Impairment: A Rare Case of Inhaled Tobramycin Induced Acute Kidney Injury in a Cystic Fibrosis Patient
por: Miller, Tyler, et al.
Publicado: (2021)

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis
por: Terpstra, Lotte C., et al.
Publicado: (2022)

Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study
por: Mainz, Jochen G, et al.
Publicado: (2014)

Trimeric Tobramycin/Nebramine Synergizes β-Lactam Antibiotics against Pseudomonas aeruginosa
por: Dhiman, Shiv, et al.
Publicado: (2023)

Exploring Antibiotic-Potentiating Effects of Tobramycin–Deferiprone Conjugates in Pseudomonas aeruginosa
por: Gandhi, Karan, et al.
Publicado: (2023)

Vasculitis in Cystic Fibrosis
por: Sposito, Francesca, et al.
Publicado: (2020)

In Vitro Inhibition of Neutrophil Elastase Activity by Inhaled Anti-Pseudomonas Antibiotics Used in Cystic Fibrosis Patients
por: Hector, Andreas, et al.
Publicado: (2010)

The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis
por: Dhand, Rajiv
Publicado: (2018)

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis
por: Li, Danni, et al.
Publicado: (2023)

Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis
por: Reverchon, Jérémy, et al.
Publicado: (2022)

Efficacy of inhaled tobramycin in severe nosocomial pneumonia
por: Kuzovlev, A, et al.
Publicado: (2012)

Inhaled tobramycin for the treatment of nosocomial pneumonia in sepsis
por: Kuzovlev, A, et al.
Publicado: (2014)

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis
por: MacLeod, David L., et al.
Publicado: (2009)

Risk of Development of Resistance in Patients with Non-Cystic Fibrosis Bronchiectasis Treated with Inhaled Antibiotics
por: Regan, Kate H., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6c22nhkub7m1jhhcudfhsrd5pi